– FOLLOWING THE FAILURE OF OUR APPLICATION FOR A EUROPEAN SUBSIDY, ONE OF OUR SHAREHOLDER COMMITS TO RAISE THE BUDGET FOR PROOF OF EFFICACY
– CC & C RECEIVES DELIVERANCE OF ITS PATENT FOR JAPAN AND THE USA
On June 20th, we received the notification of rejection of our grant application for the European call Future Emerging Technologies (FET-Open). It was supposed to fund our Proof of Efficacy experiment, that is, the experimental proof that our method can reduce the volume of human pancreatic tumors grafted into the mouse pancreas. This is obviously a great disappointment.
However, our new shareholder, TOD Finances, commits to raise the necessary funds to mount this Proof of Efficiency. The budget will be smaller than on a European grant, but will allow to carry this research action through and maintain the planned schedule: feasibilities in 2020, animal testing in 2021.